{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:59:31Z","timestamp":1793465971249,"version":"4.5.0"},"reference-count":135,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1097\/hrp.0000000000000079","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T05:17:35Z","timestamp":1425619055000},"page":"122-133","source":"Crossref","is-referenced-by-count":88,"title":["Pharmacotherapy for Alcohol Use Disorder"],"prefix":"10.1097","volume":"23","author":[{"given":"Robert M.","family":"Swift","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Aston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-7-20210129","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1176\/appi.ajp.2013.12060782","article-title":"DSM-5 criteria for substance use disorders: recommendations and rationale.","volume":"170","author":"Hasin","year":"2013","journal-title":"Am J Psychiatry"},{"key":"R4-7-20210129","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.amepre.2011.06.045","article-title":"Economic costs of excessive alcohol consumption in the U.S., 2006.","volume":"41","author":"Bouchery","year":"2011","journal-title":"Am J Prev Med"},{"key":"R5-7-20210129","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199905133401907","article-title":"Drug therapy for alcohol dependence.","volume":"340","author":"Swift","year":"1999","journal-title":"N Engl J Med"},{"key":"R6-7-20210129","first-page":"211","article-title":"How effective is alcoholism treatment in the United States J Stud A","volume":"6","author":"Miller","year":"2001","journal-title":"lcohol"},{"key":"R7-7-20210129","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1360-0443.2004.00964.x","article-title":"Recovery from DSM-IV alcohol dependence: United States, 2001-2002.","volume":"100","author":"Dawson","year":"2005","journal-title":"Addiction"},{"key":"R9-7-20210129","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1360-0443.2002.00019.x","article-title":"Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders.","volume":"97","author":"Miller","year":"2002","journal-title":"Addiction"},{"key":"R10-7-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction.","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"R11-7-20210129","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"key":"R12-7-20210129","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1369-1600.2012.00454.x","article-title":"Medications development to treat alcohol dependence: a vision for the next decade.","volume":"17","author":"Litten","year":"2012","journal-title":"Addict Biol"},{"key":"R13-7-20210129","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.","volume":"73","author":"Mann","year":"2013","journal-title":"Biol Psychiatry"},{"key":"R14-7-20210129","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0269881111408463","article-title":"Substitution therapy for alcoholism: time for a reappraisal J P","volume":"26","author":"Chick","year":"2012","journal-title":"sychopharmacol"},{"key":"R15-7-20210129","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev.physiol.66.032102.112534","article-title":"Learning mechanisms in addiction: synaptic plasticity in the ventral tegmental area as a result of exposure to drugs of abuse.","volume":"66","author":"Kauer","year":"2004","journal-title":"Annu Rev Physiol"},{"key":"R16-7-20210129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0165-0173(93)90013-P","article-title":"The neural basis of drug craving: an incentive-sensitization theory of addiction.","volume":"18","author":"Robinson","year":"1993","journal-title":"Brain Res Brain Res Rev"},{"key":"R17-7-20210129","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10550490802138400","article-title":"Effects of naltrexone during the descending limb of the blood alcohol curve.","volume":"17","author":"Ray","year":"2008","journal-title":"Am J Addict"},{"key":"R18-7-20210129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrn3745","article-title":"Neurobiology of food intake in health and disease.","volume":"15","author":"Morton","year":"2014","journal-title":"Nat Rev Neurosci"},{"key":"R19-7-20210129","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"key":"R20-7-20210129","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1176\/ajp.142.11.1259","article-title":"The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence.","volume":"142","author":"Khantzian","year":"1985","journal-title":"Am J Psychiatry"},{"key":"R21-7-20210129","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/014107689608900711","article-title":"2 dopamine receptor gene as a determinant of reward deficiency syndrome.","volume":"89","author":"Blum","year":"1996","journal-title":"J R Soc Med"},{"key":"R22-7-20210129","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/archneur.64.11.1575","article-title":"Dopamine in drug abuse and addiction: results of imaging studies and treatment implications.","volume":"64","author":"Volkow","year":"2007","journal-title":"Arch Neurol"},{"key":"R23-7-20210129","first-page":"310","article-title":"How adaptation of the brain to alcohol leads to dependence: a pharmacological perspective.","volume":"31","author":"Clapp","year":"2008","journal-title":"Alcohol Res Health"},{"key":"R24-7-20210129","first-page":"13","article-title":"Neurochemical mechanisms underlying alcohol withdrawal.","volume":"22","author":"Littleton","year":"1998","journal-title":"Alcohol Health Res World"},{"key":"R25-7-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0893-133X(00)00195-0","article-title":"Drug addiction, dysregulation of reward, and allostasis.","volume":"24","author":"Koob","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"R26-7-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuron.2008.06.012","article-title":"A role for brain stress systems in addiction.","volume":"59","author":"Koob","year":"2008","journal-title":"Neuron"},{"key":"R27-7-20210129","first-page":"169","article-title":"Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked Addict B","volume":"15","author":"Heilig","year":"2010","journal-title":"iol"},{"key":"R28-7-20210129","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1046\/j.1360-0443.2001.96811619.x","article-title":"Cue exposure with coping skills training and communication skills training for alcohol dependence: 6- and 12-month outcomes.","volume":"96","author":"Rohsenow","year":"2001","journal-title":"Addiction"},{"key":"R29-7-20210129","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1523\/JNEUROSCI.4062-12.2013","article-title":"Rescue of infralimbic mGluR2 deficit restores control over drug-seeking behavior in alcohol dependence.","volume":"33","author":"Meinhardt","year":"2013","journal-title":"J Neurosci"},{"key":"R30-7-20210129","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11910-013-0386-8","article-title":"The functional anatomy of impulse control disorders.","volume":"13","author":"Probst","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R31-7-20210129","first-page":"166","article-title":"Genetic influences on alcoholism risk. A review on adoption and twin studies.","volume":"19","author":"Heath","year":"1995","journal-title":"Alcohol Health Res World"},{"key":"R32-7-20210129","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2174\/138920208786241252","article-title":"Molecular genetics of alcohol dependence and related endophenotypes.","volume":"9","author":"Strat","year":"2008","journal-title":"Curr Genomics"},{"key":"R33-7-20210129","first-page":"64","article-title":"Genetic research: who is at risk for alcoholism.","volume":"33","author":"Foroud","year":"2010","journal-title":"Alcohol Res Health"},{"key":"R34-7-20210129","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1176\/ajp.152.8.1219","article-title":"Alcohol and aldehyde dehydrogenase polymorphisms and the risk for alcoholism.","volume":"152","author":"Higuchi","year":"1995","journal-title":"Am J Psychiatry"},{"key":"R35-7-20210129","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/sim.3878","article-title":"Analysis of extreme drinking in patients with alcohol dependence using Pareto regression.","volume":"29","author":"Das","year":"2010","journal-title":"Stat Med"},{"key":"R36-7-20210129","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/01.ftd.0000179840.78762.33","article-title":"Genetic associations of alcohol and aldehyde dehydrogenase with alcohol dependence and their mechanisms of action.","volume":"27","author":"Wall","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R37-7-20210129","first-page":"677","article-title":"Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men.","volume":"48","author":"Thomasson","year":"1991","journal-title":"Am J Hum Genet"},{"key":"R38-7-20210129","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram: a half of a century later.","volume":"26","author":"Suh","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R39-7-20210129","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","article-title":"Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.","volume":"256","author":"Fuller","year":"1986","journal-title":"JAMA"},{"key":"R40-7-20210129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1192\/bjp.161.1.84","article-title":"Disulfiram treatment of alcoholism.","volume":"161","author":"Chick","year":"1992","journal-title":"Br J Psychiatry"},{"key":"R41-7-20210129","first-page":"65","article-title":"Disulfiram (antabuse) contracts in treatment of alcoholism.","volume":"150","author":"OFarrell","year":"1995","journal-title":"NIDA Res Monogr"},{"key":"R42-7-20210129","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1360-0443.1998.9357137.x","article-title":"Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram.","volume":"93","author":"Carroll","year":"1998","journal-title":"Addiction"},{"key":"R43-7-20210129","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence.","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R44-7-20210129","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence. A controlled study.","volume":"49","author":"OMalley","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"R45-7-20210129","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1176\/ajp.151.10.1463","article-title":"Naltrexone-induced alterations in human ethanol intoxication.","volume":"151","author":"Swift","year":"1994","journal-title":"Am J Psychiatry"},{"issue":"12","key":"R46-7-20210129","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence.","author":"Rosner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R47-7-20210129","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"R48-7-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/0269881107078308","article-title":"Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.","volume":"22","author":"Rosner","year":"2008","journal-title":"J Psychopharmacol"},{"key":"R49-7-20210129","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/sj.npp.1300219","article-title":"A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.","volume":"28","author":"Oslin","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R50-7-20210129","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","article-title":"An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.","volume":"65","author":"Anton","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"R51-7-20210129","first-page":"66","article-title":"Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage.","volume":"67","author":"Pfohl","year":"1986","journal-title":"NIDA Res Monogr"},{"key":"R54-7-20210129","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"R55-7-20210129","first-page":"1179","article-title":"Acamprosate in alcohol dependence: how does it work A","volume":"90","author":"Littleton","year":"1995","journal-title":"ddiction"},{"key":"R56-7-20210129","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/j.1530-0277.2002.tb02484.x","article-title":"Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors.","volume":"26","author":"Harris","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"key":"R57-7-20210129","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1530-0277.1998.tb03871.x","article-title":"Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain.","volume":"22","author":"Naassila","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"R58-7-20210129","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1530-0277.1998.tb03636.x","article-title":"Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons.","volume":"22","author":"Berton","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"R59-7-20210129","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1530-0277.1996.tb01667.x","article-title":"Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro.","volume":"20","author":"Madamba","year":"1996","journal-title":"Alcohol Clin Exp Res"},{"key":"R60-7-20210129","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/npp.2013.264","article-title":"Acamprosate produces its anti-relapse effects via calcium.","volume":"39","author":"Spanagel","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"R61-7-20210129","first-page":"239","article-title":"Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol.","volume":"30","author":"Paille","year":"1995","journal-title":"Alcohol Alcohol"},{"key":"R62-7-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1192\/bjp.171.1.73","article-title":"Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study.","volume":"171","author":"Pelc","year":"1997","journal-title":"Br J Psychiatry"},{"key":"R63-7-20210129","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archpsyc.1996.01830080023006","article-title":"Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence.","volume":"53","author":"Sass","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"R64-7-20210129","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jpsychires.2006.02.002","article-title":"Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.","volume":"40","author":"Mason","year":"2006","journal-title":"J Psychiatr Res"},{"key":"R65-7-20210129","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"R66-7-20210129","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/adb.12012","article-title":"Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.","volume":"18","author":"Mann","year":"2013","journal-title":"Addict Biol"},{"key":"R67-7-20210129","first-page":"275","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful A","volume":"108","author":"Maisel","year":"2013","journal-title":"ddiction"},{"key":"R68-7-20210129","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","article-title":"A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.","volume":"18","author":"Mason","year":"1994","journal-title":"Alcohol Clin Exp Res"},{"key":"R69-7-20210129","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.","volume":"56","author":"Mason","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"R70-7-20210129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","article-title":"A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence.","volume":"24","author":"Anton","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R71-7-20210129","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"Mann K; ESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.","volume":"23","author":"Gual","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"R72-7-20210129","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.alcalc.a008160","article-title":"An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects.","volume":"31","author":"Addolorato","year":"1996","journal-title":"Alcohol Alcohol"},{"key":"R73-7-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/alcalc\/agq083","article-title":"Gamma-hydroxybutyrate (GHB) for the treatment of alcohol dependence: a call for further understanding.","volume":"46","author":"Caputo","year":"2011","journal-title":"Alcohol Alcohol"},{"key":"R74-7-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0741-8329(99)00084-1","article-title":"Gamma-hydroxybutyric acid efficacy, potential abuse, and dependence in the treatment of alcohol addiction.","volume":"20","author":"Addolorato","year":"2000","journal-title":"Alcohol"},{"key":"R78-7-20210129","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomised controlled trial.","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"key":"R79-7-20210129","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial.","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"key":"R80-7-20210129","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","article-title":"Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.","volume":"171","author":"Kranzler","year":"2014","journal-title":"Am J Psychiatry"},{"key":"R81-7-20210129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1037\/a0015700","article-title":"A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.","volume":"17","author":"Ray","year":"2009","journal-title":"Exp Clin Psychopharmacol"},{"key":"R83-7-20210129","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1940-0640-8-12","article-title":"Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration.","volume":"8","author":"Del Re","year":"2013","journal-title":"Addict Sci Clin Pract"},{"key":"R84-7-20210129","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/j.1530-0277.2009.00986.x","article-title":"A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal.","volume":"33","author":"Myrick","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"R85-7-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1369-1600.2008.00133.x","article-title":"Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin.","volume":"14","author":"Mason","year":"2009","journal-title":"Addict Biol"},{"key":"R86-7-20210129","first-page":"70","article-title":"Gabapentin treatment for alcohol dependence: a randomized clinical trial.","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA"},{"key":"R87-7-20210129","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence.","volume":"168","author":"Anton","year":"2011","journal-title":"Am J Psychiatry"},{"key":"R88-7-20210129","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jama.1997.03550020076042","article-title":"Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal.","volume":"278","author":"Mayo-Smith","year":"1997","journal-title":"JAMA"},{"key":"R89-7-20210129","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/alcalc\/agl076","article-title":"Diazepam dose-dependently increases or decreases implicit priming of alcohol associations in problem drinkers.","volume":"41","author":"Zack","year":"2006","journal-title":"Alcohol Alcohol"},{"key":"R90-7-20210129","first-page":"99","article-title":"Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review.","volume":"5","author":"Brennan","year":"2013","journal-title":"Clin Pharmacol"},{"key":"R91-7-20210129","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study.","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"R92-7-20210129","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"R93-7-20210129","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial.","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"key":"R95-7-20210129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1530-0277.2007.00360.x","article-title":"A pilot double-blind treatment trial of memantine for alcohol dependence.","volume":"31","author":"Evans","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"R96-7-20210129","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4088\/JCP.v69n0308","article-title":"Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.","volume":"69","author":"Muhonen","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R97-7-20210129","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","article-title":"The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.","volume":"26","author":"Sani","year":"2012","journal-title":"CNS Drugs"},{"key":"R98-7-20210129","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.npp.1300917","article-title":"The effect of olanzapine on craving and alcohol consumption.","volume":"31","author":"Hutchison","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R99-7-20210129","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/JCP.0b013e3180ca86e5","article-title":"A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism.","volume":"27","author":"Kampman","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R100-7-20210129","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1530-0277.2011.01649.x","article-title":"A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients.","volume":"36","author":"Litten","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"R101-7-20210129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1530-0277.1996.tb01644.x","article-title":"Buspirone in the treatment of alcohol dependence: a placebo-controlled trial.","volume":"20","author":"Malec","year":"1996","journal-title":"Alcohol Clin Exp Res"},{"key":"R102-7-20210129","first-page":"221","article-title":"Clinical pharmacology of serotonin-altering medications for decreasing alcohol consumption.","volume":"2","author":"Naranjo","year":"1993","journal-title":"Alcohol Alcohol"},{"key":"R103-7-20210129","first-page":"391","article-title":"Am J P","volume":"152","year":"1995","journal-title":"sychiatry"},{"key":"R104-7-20210129","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1530-0277.2011.01609.x","article-title":"Comparison of alcoholism subtypes as moderators of the response to sertraline treatment.","volume":"36","author":"Kranzler","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"R105-7-20210129","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1530-0277.2000.tb04648.x","article-title":"Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype.","volume":"24","author":"Pettinati","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"R106-7-20210129","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial.","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"},{"key":"R107-7-20210129","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1176\/appi.ajp.2013.12091163","article-title":"Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.","volume":"170","author":"Johnson","year":"2013","journal-title":"Am J Psychiatry"},{"key":"R108-7-20210129","first-page":"655","article-title":"A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology (Berl.","volume":"215","author":"Fucito","year":"2011","journal-title":")"},{"key":"R109-7-20210129","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","article-title":"Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.","volume":"48","author":"Coe","year":"2005","journal-title":"J Med Chem"},{"key":"R110-7-20210129","first-page":"179","article-title":"Alcohols actions on neuronal nicotinic acetylcholine receptors.","volume":"29","author":"Davis","year":"2006","journal-title":"Alcohol Res Health"},{"key":"R111-7-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/dmd.105.006767","article-title":"Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.","volume":"34","author":"Obach","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"R112-7-20210129","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.tips.2007.05.003","article-title":"Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation.","volume":"28","author":"Rollema","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"R113-7-20210129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.108.147058","article-title":"The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system.","volume":"329","author":"Ericson","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"R114-7-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1530-0277.2000.tb04585.x","article-title":"Involvement of nicotinic receptors in alcohol self-administration.","volume":"24","author":"Le","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"R115-7-20210129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biopsych.2009.01.029","article-title":"Varenicline reduces alcohol self-administration in heavy-drinking smokers.","volume":"66","author":"McKee","year":"2009","journal-title":"Biol Psychiatry"},{"key":"R116-7-20210129","first-page":"453","article-title":"Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction Am J A","volume":"22","author":"Nocente","year":"2013","journal-title":"ddict"},{"key":"R117-7-20210129","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00213-012-2717-x","article-title":"Varenicline decreases alcohol consumption in heavy-drinking smokers.","volume":"223","author":"Mitchell","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"R118-7-20210129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence.","volume":"207","author":"Litten","year":"2013","journal-title":"J Addict Med"},{"key":"R119-7-20210129","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.65.7.841","article-title":"The incentive salience of alcohol: translating the effects of genetic variant in CNR1.","volume":"65","author":"Hutchison","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"R120-7-20210129","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s002130050326","article-title":"Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors.","volume":"132","author":"Arnone","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"R121-7-20210129","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/oxfordjournals.alcalc.a008368","article-title":"Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716.","volume":"33","author":"Colombo","year":"1998","journal-title":"Alcohol Alcohol"},{"key":"R122-7-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-009-1704-3","article-title":"Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers.","volume":"208","author":"George","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"R123-7-20210129","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/JCP.0b013e318172b8bc","article-title":"Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.","volume":"28","author":"Soyka","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R124-7-20210129","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/med.10049","article-title":"Anti-dipsotropic isoflavones: the potential therapeutic agents for alcohol dependence.","volume":"23","author":"Keung","year":"2003","journal-title":"Med Res Rev"},{"key":"R125-7-20210129","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1530-0277.2010.01390.x","article-title":"Kudzu extract treatment does not increase the intoxicating effects of acute alcohol in human volunteers.","volume":"35","author":"Penetar","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"key":"R126-7-20210129","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/01.ALC.0000163499.64347.92","article-title":"An extract of the Chinese herbal root kudzu reduces alcohol drinking by heavy drinkers in a naturalistic setting.","volume":"29","author":"Lukas","year":"2005","journal-title":"Alcohol Clin Exp Res"},{"key":"R127-7-20210129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00213-012-2884-9","article-title":"Zhaohui Su A standardized kudzu extract (NPI-031) reduces alcohol consumption in non-treatment-seeking male heavy drinkers.","volume":"226","author":"Lukas","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"R128-7-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.drugalcdep.2012.04.012","article-title":"The isoflavone puerarin reduces alcohol intake in heavy drinkers: a pilot study.","volume":"126","author":"Penetar","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"R129-7-20210129","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1530-0277.2002.tb02543.x","article-title":"Metadoxine in acute alcohol intoxication: a double-blind, randomized, placebo-controlled study.","volume":"26","author":"Shpilenya","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"key":"R130-7-20210129","first-page":"160","article-title":"Pyrrolidone carboxylic acid in acute and chronic alcoholism. Preclinical and clinical studies.","volume":"80","author":"Pellegrini-Giampietro","year":"1989","journal-title":"Recenti Prog Med"},{"key":"R131-7-20210129","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00002018-199920050-00003","article-title":"Safety issues concerning the use of disulfiram in treating alcohol dependence.","volume":"20","author":"Chick","year":"1999","journal-title":"Drug Saf"},{"key":"R132-7-20210129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncpgasthep0683","article-title":"Management strategies in alcoholic liver disease.","volume":"4","author":"Tilg","year":"2007","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"R133-7-20210129","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hup.1244","article-title":"Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease.","volume":"26","author":"Leggio","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"R134-7-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1747-597X-1-35","article-title":"A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence.","volume":"1","author":"Guerrini","year":"2006","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"R135-7-20210129","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1530-0277.2010.01334.x","article-title":"Role of feeding-related pathways in alcohol dependence: a focus on sweet preference, NPY, and ghrelin.","volume":"35","author":"Leggio","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"key":"R136-7-20210129","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1369-1600.2010.00308.x","article-title":"Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving.","volume":"17","author":"Leggio","year":"2012","journal-title":"Addict Biol"},{"key":"R137-7-20210129","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.psyneuen.2011.11.005","article-title":"The association of the appetitive peptide acetylated ghrelin with alcohol craving in early abstinent alcohol dependent individuals.","volume":"37","author":"Koopmann","year":"2012","journal-title":"Psychoneuroendocrinology"},{"key":"R138-7-20210129","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.biopsych.2014.03.019","article-title":"Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation.","volume":"76","author":"Leggio","year":"2014","journal-title":"Biol Psychiatry"},{"key":"R139-7-20210129","doi-asserted-by":"crossref","first-page":"e71284","DOI":"10.1371\/journal.pone.0071284","article-title":"Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption.","volume":"8","author":"Suchankova","year":"2013","journal-title":"PloS One"},{"key":"R140-7-20210129","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.tins.2007.06.006","article-title":"A key role for corticotropin-releasing factor in alcohol dependence.","volume":"30","author":"Heilig","year":"2007","journal-title":"Trends Neurosci"},{"key":"R141-7-20210129","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/npp.2011.268","article-title":"Mifepristone in the central nucleus of the amygdala reduces yohimbine stress-induced reinstatement of ethanol-seeking.","volume":"37","author":"Simms","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"R142-7-20210129","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/acer.12177","article-title":"Decreased alcohol consumption among former male users of finasteride with persistent sexual side effects: a preliminary report.","volume":"37","author":"Irwig","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"key":"R143-7-20210129","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1530-0277.2008.00807.x","article-title":"A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence.","volume":"33","author":"Simpson","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"R144-7-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1530-0277.2011.01628.x","article-title":"Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings.","volume":"36","author":"Fox","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"R145-7-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0740-5472(02)00319-7","article-title":"Research to practice: adoption of naltrexone in alcoholism treatment.","volume":"24","author":"Thomas","year":"2003","journal-title":"J Subst Abuse Treat"}],"container-title":["Harvard Review of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HRP.0000000000000079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:44:53Z","timestamp":1620938693000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00023727-201503000-00007"}},"subtitle":["Current and Emerging Therapies"],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":135,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/hrp.0000000000000079","relation":{},"ISSN":["1067-3229"],"issn-type":[{"value":"1067-3229","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}